louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT07006857: Effects of Exercise With Different Music Frequencies
Official title: Comparative Effects of Exercise Combined With Music at Varying Frequencies on Physical and Cognitive Performance in Young Adults
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Physical Inactivity
Keywords: Exercise
Cognition
Music Therapy
Yoga
Performance
Lead sponsor: Biruni University
Sponsor class: OTHER
Collaborators: name: The Scientific and Technological Research Council of Türkiye (TÜBİTAK)
First posted: 2025-06-05
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: This study will explore the impact of different music frequencies applied during yoga based exercises on physical performance and cognitive status in inactive young adults.

Detailed description: This study will explore the impact of different music frequencies applied during yoga based exercises on physical performance and cognitive status in inactive young adults aged between 18-35 years. Thirty participants will be randomly assigned into three groups: low-medium frequency music, high frequency music, and a control group without music.

Eligibility criteria: Inclusion Criteria:

* Being a healthy woman or man between the ages of 18-35 years,
* Not having any ongoing musculoskeletal problems that prevent doing exercise/physical activity (Will be assessed with the Physical ActivityReadiness Questionnaire).
* Being physically inactive according to the International Physical Activity Short Form
* Being a volunteer to participate in the study.
* Being able to read and understand Turkish.

Exclusion Criteria:

* Ongoing pregnancy,
* Having any hearing problems or colorblindness,
* Using regular medications with potential neurological side effects (psychiatric medications, painkillers, etc.).
* Continuing treatment due to a psychiatric diagnosis such as clinical depression, anxiety, bipolar disorder, or schizophrenia.

Primary outcomes:
measure: Stroop Test
timeFrame: 8 weeks
Secondary outcomes:
measure: Sit To Stand Test
timeFrame: 8 weeks
measure: Wall Squat test
timeFrame: 8 weeks
measure: Push Up Test
timeFrame: 8 weeks
measure: Handgrip Electronic Dynamometer
timeFrame: 8 weeks
measure: Sit And Reach
timeFrame: 8 weeks
measure: Nelson Ruler Test
timeFrame: 8 weeks
measure: Global Scale of Change
timeFrame: 8th week
Other outcomes:
Locations:
city: Zeytinburnu
country: Turkey
facility: Biruni University
state: İstanbul
Study officials:
affiliation: Biruni University
name: Begüm Kara Kaya, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00320957: Ologen (OculusGen)-Glaucoma and Pterygium Historical Control Study in China Zhong-Shan Hospital
Official title: Study of the Safety and Effectiveness of the Ologen (OculusGen) Collagen Matrix Implant as an Aid in Glaucoma and Pterygium Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Glaucomas
Pterygium
Keywords: Glaucoma
Pterygium
collagen matrix
OculusGen
trabeculectomy
Anti scarring
pterygium recurrence
tissue engineering
Aeon Astron
ologen
Lead sponsor: Pro Top & Mediking Company Limited
Sponsor class: INDUSTRY
First posted: 2006-05-03
Enrollment: 61
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether the OculusGen Collagen Matrix are effective and safe to implant as an aid of glaucoma surgery.

Detailed description: ologen (OculusGen) Collagen Matrix is a porous, scaffold matrix. It is to be implanted on the top of the scleral flap and beneath the conjunctiva and Tenon's capsule at the end of trabeculectomy. The pores in the scaffold matrix range from 20 to 200µm, a size that is suitable for fibroblasts to grow randomly, through the body of the matrix without causing scarring. The space occupied by the collagen matrix scaffold creates room for the development of a filtration bleb. Immediately after implantation, the collagen matrix is absorbed with the aqueous humor that bring a certain pressure press on the top of scleral flap which makes the dynamic balance for the aqueous system to keep the IOP in the right side. The collagen matrix is bio-degraded within 90 days and will leave a physiologic space for the filtration bleb to facilitate control of intraocular pressure (IOP).

Eligibility criteria: Inclusion Criteria:

1. Age 18 years or over
2. Patient able to cooperate with study procedures and able to perform tests reliably
3. Patient willing to sign informed consent
4. Patient able and willing to complete postoperative follow-up requirements
5. Glaucoma：one/both eyes are affected by glaucoma
6. Pterygium： patient with pterygium

Exclusion Criteria:

* Known allergic reactions to collagen

Primary outcomes:
measure: the effectiveness via the reduction of IOP and the incidence of pterygium recurrence
timeFrame: 180 day
Secondary outcomes:
measure: the safety via the incidence of complications and adverse events.
timeFrame: 180 day
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Zhongshan Hospital Fudan University
Study officials:
affiliation: Fudan University
name: Fei Yuan, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Hsu WC, Spilker MH, Yannas IV, Rubin PA. Inhibition of conjunctival scarring and contraction by a porous collagen-glycosaminoglycan implant. Invest Ophthalmol Vis Sci. 2000 Aug;41(9):2404-11.
Clinical trial NCT00150657: Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer
Official title: Phase II Trial of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Non-Small Cell Lung Cancer
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Non-Small Cell Lung Cancer
Lead sponsor: St. John Providence Health System
Sponsor class: OTHER
Collaborators: name: Genentech, Inc.
name: Eli Lilly and Company
First posted: 2005-09-08
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: * this study is being done to find out if the combination of carboplatin and gemcitabine will be more effective in the the treatment of advanced lung cancer if bevacizumab, an agent that blocks tumor blood vessel formation, is added
* the study will measure the time to progression of patients treated with the combination; we hope to show that the addition of bevacizumab improves the time to progression (increases the amount of time before the disease begins to worsen)
* all patients receive all three drugs; there is no placebo

Detailed description: * Patients with advanced (stage IV, and Stage IIIB with effusion) non-small cell lung cancer with non-squamous histology, good performance status, and adequate organ function are eligible.
* Patients with brain metastases, squamous histology, or hemoptysis are excluded.
* All patients must give informed consent.
* Schema gemcitabine 1250 mg/M2 IV day 1,8 carboplatin AUC 5 IV day 1 bevacizumab 15 mg/kg IV day 1 repeated every 21 days for 6 cycles

Eligibility criteria: Inclusion Criteria:

* Histologically or cytologically proven non-small cell lung cancer, newly diagnosed or recurrent after previous surgery and/or radiation therapy
* Stage IV disease or stage IIIB with a malignant pleural effusion
* measurable or evaluable disease
* Performance status 0 or 1 (ECOG)
* adequate renal, hepatic, and bone marrow function
* adequate recovery from previous surgery or radiotherapy
* informed consent

Exclusion Criteria:

* brain metastases
* squamous (epidermoid) histology
* hemoptysis
* central airway disease
* Pancoast tumors
* previous chemotherapy or biologic therapy for lung cancer
* prior malignancy within the previous 5 years except non-melanoma skin cancer or cervical CIS
* pregnant or nursing women

Primary outcomes:
measure: time to progression
Secondary outcomes:
measure: response rate
measure: median survival
measure: one year survival
measure: two year survival
measure: toxicity
Other outcomes:
Locations:
city: Southfield
country: United States
facility: Providence Cancer Institute
state: Michigan
Study officials:
affiliation: Providence Cancer Institute
name: Michael J Kraut, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01518257: Safety and Efficacy Study of Botulinum Toxin Type A as Treatment for Osteoarthritis Knee Pain
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Osteoarthritis
Lead sponsor: Allergan
Sponsor class: INDUSTRY
First posted: 2012-01-25
Enrollment: 121
Sex: ALL
Minimum age (years): 40
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will evaluate the efficacy and safety of a single intra-articular (IA) injection of botulinum toxin Type A compared with placebo as treatment for osteoarthritis (OA) knee pain.


Eligibility criteria: Inclusion Criteria:

* Painful osteoarthritis in the study knee
* Able to walk without assistive walking devices, able to perform usual daily activities, and agree to maintain similar activity level throughout the study

Exclusion Criteria:

* Chronic pain conditions other than knee osteoarthritis
* Presence of bursitis, meniscus tear, ligament tear, or significant injury to the study knee within 1 year
* Surgery to the study knee within 24 weeks
* Treatment with hyaluronic acid in the study knee within 24 weeks
* Treatment with corticosteroids in the study knee within 12 weeks
* Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, or amyotrophic lateral sclerosis
* Previous treatment with botulinum toxin of any serotype for any reason

Primary outcomes:
measure: Change From Baseline in the Average Daily Worst Pain Intensity Score at Week 4
timeFrame: Baseline, Week 4
measure: Change From Baseline in the Average Daily Worst Pain Intensity Score at Week 8
timeFrame: Baseline, Week 8
measure: Change From Baseline in the Average Daily Worst Pain Intensity Score at Week 12
timeFrame: Baseline, Week 12
Secondary outcomes:
measure: Change From Baseline in Western Ontario and McMaster Universities Arthritis (WOMAC™) Total Index Score
timeFrame: Baseline, Week 8
measure: Change From Baseline in WOMAC Pain Score
timeFrame: Baseline, Week 8
measure: Change From Baseline in WOMAC Physical Function Score
timeFrame: Baseline, Week 8
measure: Patient Global Impression of Change Score
timeFrame: Week 8
Other outcomes:
Locations:
city: Aalborg
country: Denmark
Study officials:
affiliation: Allergan
name: Medical Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT01245257: Effects of Prednisolone and Pentoxifylline on the Regulation of Urea Synthesis in Alcoholic Hepatitis
Official title: Effects of Prednisolone and Pentoxifylline on the Regulation of Urea Synthesis in Alcoholic Hepatitis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Alcoholic Hepatitis
Keywords: Inflammation
Urea Synthesis
Catabolism
Nitrogen balance
Lead sponsor: University of Aarhus
Sponsor class: OTHER
First posted: 2010-11-22
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CROSSOVER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with alcoholic hepatitis admitted to hospital for treatment.

Brief summary: Loss of total mass of muscles (catabolism) is a serious clinical problem in patients with alcoholic hepatitis. The liver might play an important role in this stress-catabolism by increasing the production of urea during the inflammatory process.

The purpose of this study is to examine the regulation of urea synthesis in patients with alcoholic hepatitis and to study the effect of the anti-inflammatory drugs prednisolone and pentoxifylline on this regulation.


Eligibility criteria: Inclusion Criteria:

* Alcoholic hepatitis (alcohol intake (\> 40g/day in 6 months), bilirubin \> 80 μmol/l)

Exclusion Criteria:

* Severe bacterial infections
* Other chronical inflammatory diseases
* Cancer
* Other catabolic diseases
* Treatment with prednisolone or pentoxifylline within the last 8 weeks

Primary outcomes:
measure: Functional Hepatic Nitrogen Clearance
timeFrame: At inclusion, after approximately 3 month and if severe alcoholic hepatitis also after 14 days medical treatment
Secondary outcomes:
measure: Clinical and biochemical measures of inflammation
timeFrame: At inclusion, after approximately 3 month and if severe alcoholic hepatitis also after 14 days medical treatment
Other outcomes:
Locations:
city: Aarhus
country: Denmark
facility: Department of Medicine V, Aarhus University Hospital
Study officials:
affiliation: Aarhus University Hospital
name: Karen Louise Thomsen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01052857: Efficacy of Acupuncture on Induction of Labor
Official title: Efficacy of Acupuncture on Induction of Labor
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Labor
Pregnancy
Keywords: to evaluate acupuncture as possible alternative treatment for induction of labor
Induction
treatment
posterm
Lead sponsor: University of Modena and Reggio Emilia
Sponsor class: OTHER
First posted: 2010-01-20
Enrollment: 80
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the efficacy and safety of acupuncture for the induction of labor in pregnant women at the 40 weeks + 4 days of gestation.

Detailed description: Women at 40+2-40+4 gestational age were allocated to receive acupuncture twice a week or observation in order to observe the efficacy of acupuncture in labour onset.

Eligibility criteria: Inclusion Criteria:

* Physiological pregnant women at 40 weeks + 4 days of gestation

Exclusion Criteria:

* Fetal or maternal disease

Primary outcomes:
measure: to evaluate the efficacy of acupuncture administered daily from 40 weeks + 4 days of gestation for induction of labor respect with placebo
timeFrame: 7 days
Secondary outcomes:
measure: to evaluate safety of acupuncture
timeFrame: 7 days
Other outcomes:
Locations:
city: Modena
country: Italy
facility: University of Modena and Reggio Emilia
state: Mo
city: Modena
country: Italy
facility: University of Modena and reggio emilia
Study officials:
affiliation: University of Modena and Reggio Emilia
name: facchinetti Fabio, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04292457: Namsos Anaesthesia Children Outcome Study
Official title: Namsos Anaesthesia Children Outcome Study (NACOS)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Emergence Delirium
Keywords: Pediatric Anaesthesia
Emergence Delirium
Postoperative Behavioral Changes
Sevoflurane
Propofol
Adenotonsillectomy
Lead sponsor: Helse Nord-Trøndelag HF
Sponsor class: OTHER
Collaborators: name: ØNH Legen Trondheim
name: St. Olavs Hospital
First posted: 2020-03-03
Enrollment: 761
Sex: ALL
Minimum age (years): 1
Maximum age (years): 10
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Behavioral disturbances are often seen in children after anesthesia both immediately after surgery (emergence delirium) and after discharge from hospital. Persisting behavioral changes may affect emotional and cognitive development. It is known that both type of surgery and anesthetic management affect the occurrence of behavioral disturbances. Specifically, differences in occurrence were found after sevoflurane anesthesia and propofol anesthesia, two anesthetics that are generally used in practice. However, evidence is based on methodologically weak studies.

The described occurrence of behavioral disturbances in children after anesthesia is not in line with the investigators' clinical experience, and neither are the described differences in occurrence between sevoflurane anesthesia and propofol anesthesia. This study will compare emergence delirium and behavioral changes after discharge from hospital in children who had surgery for removal of their tonsils under sevoflurane anesthesia versus propofol anesthesia.


Eligibility criteria: Inclusion Criteria:

* adenotomy and/or tonsillotomy and/or tonsillectomy
* ASA physical status class I or II

Exclusion Criteria:

* unexperienced ear-nose-throat (ENT) surgeon (ENT surgeon \< 1 year of training, ENT surgeon without experience with the use of laryngeal mask as airway during adenotomy/tonsillotomy/tonsillectomy)
* preoperative syndromes
* ASA physical status class \> 2
* missing written consent from parents/guardians

Primary outcomes:
measure: Pediatric Anesthesia Emergence Delirium Scale (PAED) ≥ 10
timeFrame: 1 hour
Secondary outcomes:
measure: Face, Legs, Activity, Cry, Consolability Scale (FLACC) ≥ 4
timeFrame: 1 hour
measure: Post Hospital Behavioral Questionnaire (PHBQ)
timeFrame: 7 days
measure: Post Hospital Behavioral Questionnaire (PHBQ)
timeFrame: 30 days
Other outcomes:
Locations:
city: Namsos
country: Norway
facility: Namsos Hospital, Nord-Trondelag Hospital Trust
state: Trøndelag
city: Trondheim
country: Norway
facility: ØNH Legen
state: Trøndelag
Study officials:
affiliation: Head of surgical Clinic, Namsos Hospital, Nord-Trondelag Hospital Trust
name: Hallvard Græslie, MD
role: STUDY_CHAIR
References:
Clinical trial NCT02865057: Assessment of Fetal Position in Active Labor
Official title: Ultrasound Examination as a Teaching Tool for Vaginal Exam Assessment of Fetal Position in Active Labor
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Education
Lead sponsor: St. Louis University
Sponsor class: OTHER
First posted: 2016-08-12
Enrollment: 12
Sex: ALL
Minimum age (years): 21
Maximum age (years): 26
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 3rd and 4th year Ob, Gyn Residents

Brief summary: Vaginal exams are used routinely in labor to assess cervical dilation and position of the baby (facing anterior, facing to the right or left side, facing towards maternal spine). This technique has a widely variable accuracy rate (24.0-85.6%). Ultrasound has been used to help confirm or correct the vaginal assessment by obstetricians, but has not been used to assess the utility of immediate feedback to improve the accuracy of vaginal assessment by physicians in training. The investigators plan to use ultrasound assessment to determine if this education is effective in increasing accuracy in the resident population.

Detailed description: Residents will be informed of the study through an education session (as a group) and then be consented individually. Each resident will complete 15 baseline exams, 20 exams with immediate ultrasound confirmation, and 15 exams for post-test baseline. Exams will take place periodically throughout the year. Both 3rd and 4th year residents will be assessed during the same time period by the MFM fellows. Ultrasounds will follow the vaginal exam as closely as possible to prepare for delivery. A picture of the fetal position (with no name or MRN) for documentation to be taken during the SOC ultrasound and kept in the research chart for the resident.

In training feedback is not always standard. This teaching tool, consistent and standard feedback with regard to the correlation between vaginal exam and ultrasound, would allow the resident to learn to assess fetal position more accurately.

Information from the maternal chart (history and delivery information) will be collected as de identified. Data will be recorded on the data collection sheet which is labeled with a code number linking the resident participant only.

Data collected from the residents will be assigned a random Code numbers used to link the subject to their data.

Code and identifiers will be kept separate. Paper copies will be kept in a locked cabinet, in a locked office, in a locked suite.

Eligibility criteria: Inclusion Criteria:

* Physicians in obstetrics training -

Exclusion Criteria:

* Physicians outside of obstetrics training.

Primary outcomes:
measure: assessing fetal position
timeFrame: Immediate
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: St. Louis University
name: Jennifer Goldkamp, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06401057: Register for Longitudinal Recording of Brain Function
Official title: Register for Longitudinal Recording of Brain Function in Patients With Brain Diseases
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Patients With Brain Masses/Lesions
Lead sponsor: University Hospital Heidelberg
Sponsor class: OTHER
First posted: 2024-05-06
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with brain masses/lesions (especially tumors (cerebral and non-cerebral, inflammation (infectious and non-infectious), vascular pathologies)

Brief summary: The aim of this observational register study is to establish a registry that completely records and compiles the data from routinely performed technical examinations (navigated transcranial magnetic stimulation, intraoperative neuromonitoring and stimulation, MRI imaging including tractography and connectome) and clinical tests over time (pre-, intra- and postoperative, under adjuvant therapy, as part of follow-up care) of patients with intracranial masses and lesions.


Eligibility criteria: Inclusion Criteria:

* Intracranial lesion
* Age ≥ 18 years
* Written consent to participate in the study

Exclusion Criteria:

* Age \< 18 years
* Patients not able to give consent
* Patients with intracranial ferromagnetic metal implants
* Patients with implanted electronic devices

Primary outcomes:
measure: Cognitive status
timeFrame: until last patient FU up to 48 months
measure: Language status
timeFrame: until last patient FU up to 48 months
measure: Motor status
timeFrame: until last patient FU up to 48 months
measure: cortical data
timeFrame: until last patient FU up to 48 months
measure: Fiber tracts
timeFrame: until last patient FU up to 48 months
measure: Fiber tracts
timeFrame: until last patient FU up to 48 months
measure: structural imaging (Connectome)
timeFrame: until last patient FU up to 48 months
Secondary outcomes:
Other outcomes:
Locations:
city: Heidelberg
country: Germany
facility: Department of Neurosurgery Heidelberg University Hospital
Study officials:
References: